3300 A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma

Autor: Van Herpen, C., Postow, M.A., Carlino, M.S., Kalkavan, H., Weise, A., Amaria, R.N., Vos, F. De, Carvajal, R.D., Matano, A., Bhansali, S., Lam, L., Yerramilli-Rao, P., Sosman, J.A.
Zdroj: In European Journal of Cancer September 2015 51 Supplement 3:S663-S663
Databáze: ScienceDirect
Externí odkaz: